Obermeier Andreas, Schneider Jochen, Harrasser Norbert, Tübel Jutta, Mühlhofer Heinrich, Pförringer Dominik, Deimling Constantin von, Foehr Peter, Kiefel Barbara, Krämer Christina, Stemberger Axel, Schieker Matthias, Burgkart Rainer, von Eisenhart-Rothe Rüdiger
Klinik für Orthopädie und Sportorthopädie, Klinikum rechts der Isar der Technischen Universität München, München, Germany.
II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität München, München, Germany.
PLoS One. 2018 Jan 9;13(1):e0190912. doi: 10.1371/journal.pone.0190912. eCollection 2018.
Surgical sutures can promote migration of bacteria and thus start infections. Antiseptic coating of sutures may inhibit proliferation of adhered bacteria and avoid such complications.
This study investigated the inhibition of viable adhering bacteria on novel antimicrobially coated surgical sutures using chlorhexidine or octenidine, a critical factor for proliferation at the onset of local infections. The medical need, a rapid eradication of bacteria in wounds, can be fulfilled by a high antimicrobial efficacy during the first days after wound closure.
As a pretesting on antibacterial efficacy against relevant bacterial pathogens a zone of inhibition assay was conducted with middle ranged concentrated suture coatings (22 μg/cm). For further investigation of adhering bacteria in detail the most clinically relevant Staphylococcus aureus (ATCC®49230™) was used. Absorbable braided sutures were coated with chlorhexidine-laurate, chlorhexidine-palmitate, octenidine-laurate, and octenidine-palmitate. Each coating type resulted in 11, 22, or 33 μg/cm drug content on sutures. Scanning electron microscopy (SEM) was performed once to inspect the coating quality and twice to investigate if bacteria have colonized on sutures. Adhesion experiments were assessed by exposing coated sutures to S. aureus suspensions for 3 h at 37°C. Subsequently, sutures were sonicated and the number of viable bacteria released from the suture surface was determined. Furthermore, the number of viable planktonic bacteria was measured in suspensions containing antimicrobial sutures. Commercially available sutures without drugs (Vicryl®, PGA Resorba®, and Gunze PGA), as well as triclosan-containing Vicryl® Plus were used as control groups.
Zone of inhibition assay documented a multispecies efficacy of novel coated sutures against tested bacterial strains, comparable to most relevant S. aureus over 48 hours. SEM pictures demonstrated uniform layers on coated sutures with higher roughness for palmitate coatings and sustaining integrity of coated sutures. Adherent S. aureus were found via SEM on all types of investigated sutures. The novel antimicrobial sutures showed significantly less viable adhered S. aureus bacteria (up to 6.1 log) compared to Vicryl® Plus (0.5 log). Within 11 μg/cm drug-containing sutures, octenidine-palmitate (OL11) showed the highest number of viable adhered S. aureus (0.5 log), similar to Vicryl® Plus. Chlorhexidine-laurate (CL11) showed the lowest number of S. aureus on sutures (1.7 log), a 1.2 log greater reduction. In addition, planktonic S. aureus in suspensions were highly inhibited by CL11 (0.9 log) represents a 0.6 log greater reduction compared to Vicryl® Plus (0.3 log).
Novel antimicrobial sutures can potentially limit surgical site infections caused by multiple pathogenic bacterial species. Therefore, a potential inhibition of multispecies biofilm formation is assumed. In detail tested with S. aureus, the chlorhexidine-laurate coating (CL11) best meets the medical requirements for a fast bacterial eradication. This suture coating shows the lowest survival rate of adhering as well as planktonic bacteria, a high drug release during the first-clinically most relevant- 48 hours, as well as biocompatibility. Thus, CL11 coatings should be recommended for prophylactic antimicrobial sutures as an optimal surgical supplement to reduce wound infections. However, animal and clinical investigations are important to prove safety and efficacy for future applications.
手术缝线可促进细菌迁移,从而引发感染。对缝线进行抗菌涂层处理可能会抑制附着细菌的增殖,避免此类并发症。
本研究调查了使用洗必泰或奥替尼啶的新型抗菌涂层手术缝线对存活附着细菌的抑制作用,这是局部感染开始时细菌增殖的关键因素。在伤口闭合后的头几天内,通过高抗菌效力可满足迅速清除伤口细菌这一医学需求。
作为对相关细菌病原体抗菌效果的预测试,使用中等浓度的缝线涂层(22 μg/cm)进行抑菌圈试验。为进一步详细研究附着细菌,使用了临床上最相关的金黄色葡萄球菌(ATCC®49230™)。可吸收编织缝线分别用月桂酸洗必泰、棕榈酸洗必泰、月桂酸奥替尼啶和棕榈酸奥替尼啶进行涂层处理。每种涂层类型在缝线上产生的药物含量分别为11、22或33 μg/cm。进行一次扫描电子显微镜(SEM)检查涂层质量,进行两次检查以调查细菌是否已在缝线上定殖。通过将涂层缝线在37°C下暴露于金黄色葡萄球菌悬液3小时来评估粘附实验。随后,对缝线进行超声处理,并测定从缝线表面释放的存活细菌数量。此外,在含有抗菌缝线的悬液中测量存活浮游细菌的数量。将不含药物的市售缝线(Vicryl®、PGA Resorba®和Gunze PGA)以及含三氯生的Vicryl® Plus用作对照组。
抑菌圈试验证明新型涂层缝线对受试菌株具有多种抗菌效果,在48小时内与最相关的金黄色葡萄球菌相当。SEM图片显示涂层缝线上有均匀的层,棕榈酸涂层的粗糙度更高,且涂层缝线保持完整。通过SEM在所有类型的受试缝线上均发现了附着的金黄色葡萄球菌。与Vicryl® Plus(0.5 log)相比,新型抗菌缝线附着的存活金黄色葡萄球菌明显更少(高达6.1 log)。在含11 μg/cm药物的缝线中,棕榈酸奥替尼啶(OL11)附着的存活金黄色葡萄球菌数量最多(0.5 log),与Vicryl® Plus相似。月桂酸洗必泰(CL11)在缝线上的金黄色葡萄球菌数量最少(1.7 log),减少量多1.2 log。此外,CL11对悬液中的浮游金黄色葡萄球菌有高度抑制作用(0.9 log),与Vicryl® Plus(0.3 log)相比,减少量多0.6 log。
新型抗菌缝线可能会限制由多种致病细菌引起的手术部位感染。因此,推测可能会抑制多种生物膜的形成。在对金黄色葡萄球菌进行详细测试时,月桂酸洗必泰涂层(CL11)最符合快速清除细菌的医学要求。这种缝线涂层显示附着细菌和浮游细菌的存活率最低,在临床上最相关的头48小时内药物释放量高,且具有生物相容性。因此,应推荐CL11涂层作为预防性抗菌缝线,作为减少伤口感染的最佳手术补充。然而,动物和临床研究对于证明其在未来应用中的安全性和有效性很重要。